HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$30.20
Day range
$29.71 - $31.02
Year range
$22.24 - $45.99
Market cap
1.78B USD
Avg Volume
894.80K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 19.97M | 86.09% |
Operating expense | 51.61M | -0.17% |
Net income | -108.04M | -11.93% |
Net profit margin | -541.09 | 39.85% |
Earnings per share | -1.85 | -6.32% |
EBITDA | -120.31M | 2.72% |
Effective tax rate | 0.93% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 854.42M | -4.40% |
Total assets | 1.30B | -22.00% |
Total liabilities | 104.11M | -14.83% |
Total equity | 1.19B | — |
Shares outstanding | 58.59M | — |
Price to book | 1.48 | — |
Return on assets | -22.66% | — |
Return on capital | -23.73% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -108.04M | -11.93% |
Cash from operations | -96.21M | 27.75% |
Cash from investing | 90.08M | 283.24% |
Cash from financing | 2.56M | -47.19% |
Net change in cash | -3.58M | 97.98% |
Free cash flow | -62.05M | 42.58% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
540
